Client News

EsoCap and Upadia sign exclusive licensing agreement combining EsoCap technology with Upadia antibodies for the treatment of Barrett’s esophagus

Atriva Therapeutics receives U.S. FDA Orphan Drug Designation for Zapnometinib to treat Hantavirus Infections

Adocia announces its financial calendar for 2022

InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa

AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China

LINDIS Biotech Announces Formation of Advisory Board to Support Next Phase of Growth

ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2022

Atriva Therapeutics: Participation in upcoming scientific and industry conferences

VisionHealth receives EU Medical Device Regulation certification

MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval